Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

A Comprehensive Index for Predicting Risk of Anemia from Patients' Diagnoses.

Tuck MG, Alemi F, Shortle JF, Avramovic S, Hesdorffer C.

Big Data. 2017 Mar;5(1):42-52. doi: 10.1089/big.2016.0073.

PMID:
28328253
2.

Drug-Induced Megaloblastic Anemia.

Hesdorffer CS, Longo DL.

N Engl J Med. 2016 Feb 18;374(7):696-7. doi: 10.1056/NEJMc1515180. No abstract available.

PMID:
26886541
3.

Drug-Induced Megaloblastic Anemia.

Hesdorffer CS, Longo DL.

N Engl J Med. 2015 Oct 22;373(17):1649-58. doi: 10.1056/NEJMra1508861. Review. No abstract available.

PMID:
26488695
4.

Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice.

Mirsoian A, Bouchlaka MN, Sckisel GD, Chen M, Pai CC, Maverakis E, Spencer RG, Fishbein KW, Siddiqui S, Monjazeb AM, Martin B, Maudsley S, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Taub DD, Murphy WJ.

J Exp Med. 2014 Nov 17;211(12):2373-83. doi: 10.1084/jem.20140116. Epub 2014 Nov 3.

5.

Unexplained anaemia in the elderly is characterised by features of low grade inflammation.

Artz AS, Xue QL, Wickrema A, Hesdorffer C, Ferrucci L, Langdon JM, Walston JD, Roy CN.

Br J Haematol. 2014 Oct;167(2):286-9. doi: 10.1111/bjh.12984. Epub 2014 Jun 17. No abstract available.

6.

Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy.

Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, Monjazeb AM, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Redelman D, Taub DD, Murphy WJ.

J Exp Med. 2013 Oct 21;210(11):2223-37. doi: 10.1084/jem.20131219. Epub 2013 Sep 30.

7.

Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C, Biragyn A.

Cancer Res. 2013 Apr 1;73(7):2127-38. doi: 10.1158/0008-5472.CAN-12-4184. Epub 2013 Jan 30.

8.

Distinct energy requirements for human memory CD4 T-cell homeostatic functions.

Taub DD, Hesdorffer CS, Ferrucci L, Madara K, Schwartz JB, Goetzl EJ.

FASEB J. 2013 Jan;27(1):342-9. doi: 10.1096/fj.12-217620. Epub 2012 Sep 12.

9.

Association of the red cell distribution width with red blood cell deformability.

Patel KV, Mohanty JG, Kanapuru B, Hesdorffer C, Ershler WB, Rifkind JM.

Adv Exp Med Biol. 2013;765:211-216. doi: 10.1007/978-1-4614-4989-8_29.

10.

Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

Lim H, Kane L, Schwartz JB, Hesdorffer CS, Deeks SG, Greig N, Ferrucci L, Goetzl EJ.

Clin Exp Immunol. 2012 Aug;169(2):182-9. doi: 10.1111/j.1365-2249.2012.04603.x.

11.

Long-term survival of older breast cancer patients: population-based estimates over three decades.

Kanapuru B, Ershler WB, Hesdorffer C, Jemal A, Yates JW.

Breast Cancer Res Treat. 2012 Jul;134(2):853-7. doi: 10.1007/s10549-012-2115-4. Epub 2012 Jun 19.

PMID:
22710707
12.

Distinctive immunoregulatory effects of adenosine on T cells of older humans.

Hesdorffer CS, Malchinkhuu E, Biragyn A, Mabrouk OS, Kennedy RT, Madara K, Taub DD, Longo DL, Schwartz JB, Ferrucci L, Goetzl EJ.

FASEB J. 2012 Mar;26(3):1301-10. doi: 10.1096/fj.11-197046. Epub 2011 Nov 25.

13.

Thymic stromal lymphopoietin is a key mediator of breast cancer progression.

Olkhanud PB, Rochman Y, Bodogai M, Malchinkhuu E, Wejksza K, Xu M, Gress RE, Hesdorffer C, Leonard WJ, Biragyn A.

J Immunol. 2011 May 15;186(10):5656-62. doi: 10.4049/jimmunol.1100463. Epub 2011 Apr 13.

14.

Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer.

Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS.

Bone Marrow Transplant. 2007 Aug;40(3):267-72. Epub 2007 Jun 11.

PMID:
17563739
15.

Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.

Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D.

Transplantation. 2007 Mar 15;83(5):539-45.

PMID:
17353770
16.

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.

Valmori D, Lévy F, Godefroy E, Scotto L, Souleimanian NE, Karbach J, Tosello V, Hesdorffer CS, Old LJ, Jager E, Ayyoub M.

Clin Immunol. 2007 Feb;122(2):163-72. Epub 2006 Oct 24.

PMID:
17064965
17.

Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE.

Hirano M, Martí R, Casali C, Tadesse S, Uldrick T, Fine B, Escolar DM, Valentino ML, Nishino I, Hesdorffer C, Schwartz J, Hawks RG, Martone DL, Cairo MS, DiMauro S, Stanzani M, Garvin JH Jr, Savage DG.

Neurology. 2006 Oct 24;67(8):1458-60. Epub 2006 Sep 13.

18.

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.

PMID:
16505437
19.

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.

Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C.

Hum Gene Ther. 2006 Feb;17(2):239-44.

PMID:
16454657
20.

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer.

Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat LT, Savage DG, MacArthur RB, Hesdorffer C.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):57-64.

PMID:
16445611
21.

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.

Clin Immunol. 2006 Feb-Mar;118(2-3):188-94. Epub 2005 Dec 20.

PMID:
16368270
22.

Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.

Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M.

Clin Immunol. 2005 Nov;117(2):161-7. Epub 2005 Aug 15.

PMID:
16103015
23.

Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.

Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL, Vahdat LH, Lo KM, Skerrett D, Bernstein D, Sharpe E, Savage DG.

Bone Marrow Transplant. 2005 Sep;36(6):491-7.

PMID:
16044139
24.

A peripheral circulating compartment of natural naive CD4 Tregs.

Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M.

J Clin Invest. 2005 Jul;115(7):1953-62.

25.

Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.

Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):271-6.

PMID:
15997923
26.

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ, Ayyoub M.

Clin Immunol. 2005 Oct;117(1):24-30.

PMID:
15994128
27.

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.

Spanknebel K, Cheung KY, Stoutenburg J, Hurst-Wicker K, Hesdorffer C, Deraffele G, Kaufman HL.

Ann Surg Oncol. 2005 May;12(5):381-90. Epub 2005 Apr 4.

PMID:
15915372
28.

CD4+ T cell responses to SSX-4 in melanoma patients.

Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D.

J Immunol. 2005 Apr 15;174(8):5092-9.

29.

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.

Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.

Clin Immunol. 2005 Jan;114(1):70-8.

PMID:
15596411
30.

Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.

Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, Savage D, Troxel A.

Breast. 2004 Aug;13(4):341-6.

PMID:
15325671
31.

The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D.

Cancer Immun. 2004 Aug 9;4:7.

32.

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.

Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC, Valmori D.

J Immunol. 2004 Jun 1;172(11):7206-11.

33.

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D.

J Clin Invest. 2004 Apr;113(8):1225-33.

34.

Shifting gene expression profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy.

Moschella F, Catanzaro RP, Bisikirska B, Sawczuk IS, Papadapoulos KP, Ferrante AW Jr, McKiernan JM, Hesdorffer CS, Harris PE, Maffei A.

Oncol Res. 2003;14(3):133-45.

PMID:
14760862
35.

SSX antigens as tumor vaccine targets in human sarcoma.

Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D.

Cancer Immun. 2003 Oct 9;3:13.

36.

Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer.

Kaufman HL, Cheung K, Haskall Z, Horig H, Hesdorffer C, Panicali D, DeRaffele G, Spanknebel K.

Hum Gene Ther. 2003 May 20;14(8):803-27. No abstract available.

PMID:
12804142
37.

Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy.

Moschella F, Bisikirska B, Maffei A, Papadopoulos KP, Skerrett D, Liu Z, Hesdorffer CS, Harris PE.

Clin Cancer Res. 2003 Jun;9(6):2022-31.

38.

A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia.

Valmori D, Ayyoub M, Hesdorffer CS, Keilholz U, Scheibenbogen C.

Blood. 2003 Jun 1;101(11):4643-4. No abstract available.

PMID:
12756165
39.
40.

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.

Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ, Bar M, del Prete S, March R, Lonberg M, Talbot S, Mears JG, Flamm M, Taub RN, Nichols G.

Leuk Lymphoma. 2003 Mar;44(3):477-81.

PMID:
12688318
41.

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P, Cerottini JC, Hesdorffer CS, Old LJ, Valmori D.

J Clin Invest. 2002 Dec;110(12):1813-22.

42.

Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.

Nichols G, de Castro K, Wei LX, Griffin M, Lin N, Oratzi A, Murty VV, Troxel A, Vahdat L, Hesdorffer C.

Leukemia. 2002 Sep;16(9):1673-9.

43.

Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS.

Bone Marrow Transplant. 2002 Aug;30(3):149-55.

44.

Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis.

Kumar KS, Lefkowitch J, Russo MW, Hesdorffer C, Kinkhabwala M, Kapur S, Emond JC, Brown RS Jr.

Gastroenterology. 2002 Jun;122(7):2026-31.

PMID:
12055607
45.

Haploidentical 'megadose' stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings.

Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y, Schmitz N.

Leukemia. 2002 Mar;16(3):427-8. Review. No abstract available.

46.

Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature.

Lin J, Markowitz GS, Nicolaides M, Hesdorffer CS, Appel GB, D'Agati VD, Savage DG.

Am J Nephrol. 2001 Sep-Oct;21(5):351-6. Review.

PMID:
11684793
47.

Tandem transplantation in lymphoma.

Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS.

Bone Marrow Transplant. 2001 Sep;28(6):529-35. Review.

48.
49.

Reduction of paclitaxel-induced peripheral neuropathy with glutamine.

Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C.

Clin Cancer Res. 2001 May;7(5):1192-7.

50.

The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.

Papadopoulos KP, Egorin MJ, Huang M, Troxel AB, Kaufman E, Balmaceda CM, Vahdat LT, Hesdorffer CS.

Cancer Chemother Pharmacol. 2001;47(1):45-50.

PMID:
11221961

Supplemental Content

Loading ...
Support Center